Axsome Therapeutics
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $104,762 | $87,166 | $74,999 | $71,530 |
Gross Profit | 96,325 | 79,111 | 66,871 | 64,152 |
EBITDA | -60,563 | -78,046 | -65,444 | -96,533 |
EBIT | -62,624 | -80,039 | -67,275 | -98,273 |
Net Income | -64,602 | -79,345 | -68,357 | -98,651 |
Net Change In Cash | 104,762 | 87,166 | 74,999 | 71,530 |
Free Cash Flow | -18,481 | -30,162 | -53,565 | -30,369 |
Cash | 327,341 | 315,657 | 331,441 | 386,193 |
Basic Shares | 48,140 | 47,573 | 47,393 | 47,329 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $270,600 | $50,037 | $8,819 | $0 |
Gross Profit | 244,535 | 44,839 | -1,155 | -77 |
EBITDA | -224,991 | -174,234 | -123,551 | -99,063 |
EBIT | -231,825 | -179,799 | -124,706 | -99,141 |
Net Income | -239,238 | -197,766 | -134,943 | -105,388 |
Net Change In Cash | 270,600 | 50,037 | 8,819 | 0 |
Cost of Revenue | -97,403 | -36,089 | ||
Free Cash Flow | -145,662 | -117,212 | -108,533 | -78,502 |
Cash | 386,193 | 200,841 | 86,472 | 183,876 |
Basic Shares | 45,425 | 40,655 | 37,618 | 37,206 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$1.34 |
2024-06-30 | -$1.67 |
2024-03-31 | -$1.44 |
2023-12-31 | -$2.08 |
